8/109 sources · 8 publishersUpdated Oct 22, 16:52 UTC
FDA accepts Biohaven’s Vyglxia resubmission and sets Q1 2027 review goal
On October 22, 2026, Biohaven said the FDA accepted its resubmitted application for Vyglxia, also known as troriluzole, for spinocerebellar ataxia. The agency set a user fee goal date in Q1 2027 and plans to convene an advisory committee, while Biohaven included additional supportive analyses in the filing.
Why it matters
The decision puts Biohaven’s lead regulatory program on a defined FDA timetable and creates an advisory-panel milestone before the agency’s decision. The panel’s recommendation is not binding, so approval remains unresolved.
Key facts
- 1The FDA accepted Biohaven’s resubmission and set a review goal date in Q1 2027. tradingview.com
- 2The FDA plans to convene an advisory committee, but the meeting date has not been announced. tradingview.com
- 3The FDA treated the resubmission as a complete response to its Complete Response Letter issued in November 2025. investing.com
- 4Clinical data cited in the report showed 50–70% slowing of disease progression over a three-year study period. investing.com
- 5In early trading, Biohaven shares gained $3.48, equal to 29.62%, reaching $15.23. ibtimes.com.au
Open questions
- One report gives the FDA decision timing as Q1 2024, while the other event reports give Q1 2027.
- Reports differ on the timing of the prior rejection, citing November 2023 and November 2025.
Summary written by AlphAI AI Desk from 9 of 9 sources. Not investment advice. Figures are as stated by the linked sources.